Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines

作者：Wenxin Luo, Jiadi Gan, Zhu Luo, Shuangqing Li, Zhoufeng Wang, Jiaxuan Wu, Huohuo Zhang, Jinghong Xian, Ruixin Cheng, Xiumei Tang, Yi Liu, Ning Yang, Qianqian Mou, Xue Zhang, Yi Chen, Weiwen Wang, Yantong Wang, Lin Bai, Xuan Wei, Rui Zhang, Lan Yang, Yaxin Chen, Li Yang, Yalun Li, Dan Liu, Weimin Li, Lei Chen · 发表于：Signal Transduction and Targeted Therapy · 年份：2024 · DOI：10.1038/s41392-024-01751-1 · 被引用次数：9 · 研究领域：SARS-CoV-2 and COVID-19 Research、Vaccine Coverage and Hesitancy、COVID-19 Clinical Research Studies

Abstract Vaccines have proven effective in protecting populations against COVID-19, including the recombinant COVID-19 vaccine (Sf9 cells), the first approved recombinant protein vaccine in China. In this positive-controlled trial with 85 adult participants (Sf9 cells group: n = 44; CoronaVac group: n = 41), we evaluated the safety, immunogenicity, and protective effectiveness of a heterologous boost with the Sf9 cells vaccine in adults who had been vaccinated with the inactivated vaccine, and found a post-booster adverse events rate of 20.45% in the Sf9 cells group and 31.71% in the CoronaVac group ( p = 0.279), within 28 days after booster injection. Neither group reported any severe adverse events. Following the Sf9 cells vaccine booster, the geometric mean titer (GMT) of binding antibodies to the receptor-binding domain of prototype SARS-CoV-2 on day 28 post-booster was significantly higher than that induced by the CoronaVac vaccine booster (100,683.37 vs. 9,451.69, p < 0.001). In the Sf9 cells group, GMTs of neutralizing antibodies against pseudo SARS-CoV-2 viruses (prototype and diverse variants of concern [VOCs]) increased by 22.23–75.93 folds from baseline to day 28 post-booster, while the CoronaVac group showed increases of only 3.29–10.70 folds. Similarly, neutralizing antibodies against live SARS-CoV-2 viruses (prototype and diverse VOCs) increased by 68.18–192.67 folds on day 14 post-booster compared with the baseline level, significantly greater than the Coron...